moomoo ID:NaN
Log Out
Log in to access Online Inquiry

Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

Defense World ·  {{timeTz}}

Stock analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report released on Tuesday. The firm set a "sell" rating on the biotechnology company's stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH opened at $1.14 on Tuesday. The stock's 50-day simple moving average is $1.30 and its 200 day simple moving average is $1.39. Bellerophon Therapeutics has a 52-week low of $0.67 and a 52-week high of $4.49. The stock has a market capitalization of $10.88 million, a price-to-earnings ratio of -0.58 and a beta of -0.02.

Get Bellerophon Therapeutics alerts:

Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last released its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.18. On average, research analysts forecast that Bellerophon Therapeutics will post -2.21 earnings per share for the current fiscal year.

Institutional Trading of Bellerophon Therapeutics

A hedge fund recently raised its stake in Bellerophon Therapeutics stock. Renaissance Technologies LLC raised its holdings in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) by 13.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 209,399 shares of the biotechnology company's stock after acquiring an additional 24,100 shares during the period. Renaissance Technologies LLC owned approximately 2.19% of Bellerophon Therapeutics worth $258,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.92% of the company's stock.

About Bellerophon Therapeutics

(Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Read More

  • Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
  • 3 Stocks Growing Their Businesses for 2023
  • China -Based EV Maker BYD Set For Big European, Japanese Expansion
  • Is Illumina Still the Gamechanger in Genomics Sequencing?
  • Here's What Makes Amazon a Sum-of-All-Parts Commerce Juggernaut
  • The Institutions Bought CarMax In Q3, Now It's Cheaper

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.